Akeso's Ivonescimab: New Hope for Rare Biliary Tract Cancer

HONG KONG – February 05, 2026 – Biopharmaceutical firm Akeso, Inc. announced today that its flagship drug, ivonescimab, has received a Breakthrough Therapy Designation (BTD) from China's National Medical Products Administration (NMPA). This marks the fifth such designation for the innovative antibody but represents a crucial new front: the first-line treatment of advanced biliary tract cancer (BTC), a rare but highly aggressive group of malignancies.

The designation, which is intended to accelerate the development and review of promising new medicines, signals a potential paradigm shift for patients battling a disease with historically grim prospects and limited therapeutic options.

A New Horizon for a Difficult Cancer

Biliary tract cancer, which encompasses cancers of the bile ducts and gallbladder, is notoriously difficult to treat. It is often diagnosed at an advanced, inoperable stage, leading to a poor prognosis. For years, the global standard of care for first-line treatment has been a combination of chemotherapy drugs, gemcitabine and cisplatin, which offers a median overall survival of just under one year.

More recently, the addition of immunotherapy has offered an incremental benefit. The landmark TOPAZ-1 clinical trial showed that adding the PD-L1 inhibitor durvalumab to chemotherapy extended median overall survival to 12.8 months. While a welcome advance, the need for more effective treatments remains urgent.

This is the context into which ivonescimab enters. The BTD was granted based on compelling data from a Phase 1b/II study presented at the 2024 American Society of Clinical Oncology (ASCO) meeting. In that study, ivonescimab combined with chemotherapy demonstrated an objective response rate (ORR) of 63.6%, meaning nearly two-thirds of patients saw their tumors shrink significantly. Even more impressively, the disease control rate (DCR) was 100%, indicating that all patients in the study experienced either tumor shrinkage or disease stabilization.

Most importantly, the survival metrics from the early-phase study point toward a substantial potential improvement. Patients receiving the ivonescimab regimen had a median overall survival of 16.8 months, a meaningful leap beyond the current standard of care. These results provide a strong foundation for the ongoing Phase III registrational trial, HARMONi-GI1, which has already completed patient enrollment and will provide the definitive data needed for potential approval.

The Power of a Dual-Action Approach

Ivonescimab is not just another immunotherapy drug. It is a first-in-class bispecific antibody, representing a new frontier in cancer therapy. Developed using Akeso's proprietary Tetrabody platform, this single molecule is engineered to perform two critical tasks simultaneously.

One arm of the antibody blocks PD-1, a checkpoint protein on immune cells that cancer often exploits to hide from the body's defenses. By blocking PD-1, ivonescimab effectively releases the brakes on the immune system, unleashing T-cells to identify and attack cancer cells.

Simultaneously, its second arm targets and blocks VEGF, a key protein that tumors secrete to stimulate the growth of new blood vessels in a process called angiogenesis. This network of blood vessels supplies the tumor with the oxygen and nutrients it needs to grow and spread. By inhibiting VEGF, ivonescimab aims to choke off this supply line, effectively starving the tumor. This anti-angiogenic effect can also normalize the tumor's chaotic vasculature, which may further enhance the ability of immune cells to penetrate the tumor and carry out their attack.

This dual-pronged mechanism is hypothesized to create a powerful synergy that is more effective than targeting each pathway with separate drugs. The promising results seen not only in biliary tract cancer but across multiple tumor types suggest this innovative approach is paying clinical dividends.

Navigating China's Fast Track to Market

The Breakthrough Therapy Designation from the NMPA's Center for Drug Evaluation (CDE) is more than a symbolic honor. It is a formal regulatory tool designed to expedite the path to market for drugs that demonstrate substantial improvement over available therapies for serious conditions. The program, initiated in 2020, has stringent criteria, and securing a BTD provides a company with enhanced communication with regulators and eligibility for a prioritized review of its final marketing application.

For Akeso, this is a well-trodden path. The BTD for biliary tract cancer is the fifth granted to ivonescimab in China. The drug has already received three separate designations for various non-small cell lung cancer (NSCLC) indications and another for triple-negative breast cancer (TNBC). This remarkable track record for a single asset underscores the broad potential of its dual-targeting mechanism and Akeso's ability to generate the compelling clinical data required to meet the high bar for this accelerated pathway.

This repeated regulatory validation positions ivonescimab as a potential "pipeline in a product" and a cornerstone of Akeso's oncology portfolio. It also highlights the company's strategic acumen in navigating complex regulatory environments to bring its innovations to patients more quickly.

Akeso's Strategic Ascent in Oncology

The success of ivonescimab is a powerful validation of Akeso's research and development strategy. The Hong Kong-listed company (HKEX: 9926) has invested heavily in building a multi-functional platform for discovering and developing novel biologic drugs. The consistent stream of positive data and regulatory milestones for ivonescimab solidifies its position as a leading innovator in China's competitive biopharmaceutical landscape with growing global recognition.

All eyes are now on the pivotal Phase III HARMONi-GI1 study. The trial is confidently designed to demonstrate the superiority of the ivonescimab-chemotherapy combination directly against the current immunotherapy standard of care, the durvalumab-chemotherapy regimen. A positive outcome would not only pave the way for full regulatory approval but could also establish ivonescimab as the new global standard for the first-line treatment of this devastating cancer.

As the data from this and other late-stage trials mature, the full clinical and commercial potential of this versatile bispecific antibody will become clearer. For now, the latest breakthrough designation provides a tangible beacon of hope for thousands of patients and their families facing a diagnosis of advanced biliary tract cancer.